Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
What Are Gilead Sciences’ Key Growth Drivers in Fiscal 2019?

TAF (Tenofovir alafenamide)-based HIV therapy Biktarvy and cell therapy Yescarta emerged as the key growth drivers for Gilead Sciences (GILD) in the first quarter. Besides these drugs, the company also expects HIV PrEP (pre-exposure prophylaxis therapies) Truvada and Descovy to be its key growth drivers in the future.

Published
26 June 2019
From
Market Realist
Desperate patients turn to buyers clubs

What do you do when the NHS won’t buy the treatment you need?

Published
25 June 2019
From
The Economist (free registration required)
US: HIV Advocacy Group Spars With Express Scripts Over HIV Drug Formulary Changes

Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the U.S., recently updated its list of preferred medicines to exclude seven common HIV drugs, swapping those drugs for 18 "preferred alternatives."

Published
17 June 2019
From
The BodyPro
CytoDyn: Uncovering An Opportunity

CytoDyn is moving their PRO 140 product candidate closer towards an FDA approval in HIV.

Published
12 June 2019
From
Seeking Alpha
Global ingredient shortage caused ARV stockouts

A worldwide shortage of an active pharmaceutical ingredient is the reason behind the anti-retroviral (ARV) medication shortfall across the country, the department of health confirmed. The anti-retroviral drug called Lamivudine is currently in short supply globally and this has affected ARVs that contain this ingredient.

Published
07 June 2019
From
Health-e
This drug could end HIV. Why hasn't it? (Podcast)

Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened.

Published
06 June 2019
From
New York Times
WHO agrees watered-down resolution on transparency in drug costs

Countries at the World Health Organization agreed on Tuesday to push for clearer drug pricing, after watering down a draft resolution that would have also required pharmaceutical firms to disclose the cost of making medicines.

Published
02 June 2019
From
Reuters
World Health Assembly Approves Milestone Resolution On Price Transparency

The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor. In a highly unusual move, Germany, the United Kingdom and Hungary “disassociated” themselves from the measure, “Improving the transparency of markets for medicines, vaccines and other health products,” complaining that its far-reaching implications were not fully appreciated, and that the four-month review period since the draft resolution’s submission by lead sponsor Italy had been insufficient.

Published
02 June 2019
From
Health Policy Watch
Is Off-Label HIV Prevention Better Than None?

Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.

Published
31 May 2019
From
MedPage Today (requires free registration)
The truth is you can afford the medication that prevents HIV. Here’s how.

It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.

Published
24 May 2019
From
LGBTQ Nation

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.